Back to top
more

Virtus Biotech Clinical Trials ETF: (BBC)

(Delayed Data from NYSE) As of Nov 20, 2026 03:59 PM ET

$38.17 USD

38.17
53,413

-1.60 (-4.02%)

Volume: 53,413

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $38.55 +0.38 (1.00 %) 7:58 PM ET

Zacks News

Sweta Killa headshot

Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?

Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.

Sweta Killa headshot

Top and Flop ETFs at Half-Way Q4

We have highlighted both the best and worst performing zones and their ETFs at halfway Q4.

Sanghamitra Saha headshot

ETF Areas That Spooked Investors in October

These ETF areas lost the most in the Halloween month and gave investors the chills.

Sanghamitra Saha headshot

Scared of a September Lull? Play 6 ETFs

These ETFs may perform well in ill-famed September due to solid fundamentals.

    Sanghamitra Saha headshot

    5 ETFs to Play in July

    Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.

      Sweta Killa headshot

      5 Safe and Sound ETF Strategies for 2H

      After a bumpy ride in the first half of the year, global stocks are bouncing back despite the trade war fears.

        Sweta Killa headshot

        How to Build a Winning ETF Portfolio Amid Trade War Fears

        We have highlighted some strategies that could prove extremely beneficial for investors in a choppy market.

          Sweta Killa headshot

          Sarepta Pharma Pushes Two Biotech ETFs to New Highs

          The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

            Neena Mishra headshot

            Why These Small Cap Biotech ETFs are Soaring

            These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

              Sweta Killa headshot

              Best and Worst ETFs of Last Week

              Several ETFs saw a huge decline while a few stood tall in the market turbulence.